Efficacy of simplified bladder training in patients with overactive bladder receiving a solifenacin flexible‐dose regimen: results from a randomized study

Mattiasson, Anders; Masala, Alberto; Morton, Richard E.; Bolodeoku, John

doi:10.1111/j.1464-410x.2009.08910.x

Cited by 29 publications

(39 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, drugs are sometimes associated with adverse events, such as dry mouth, dyspepsia, nausea and constipation, and some patients are refractory to these drugs . The cure rate of bladder training varies from 25 to 97%, possibly depending on the patient's cognitive ability or motivation . Neuromodulation may be an effective alternative to drug therapy for OAB.…”

Section: Introductionmentioning

confidence: 99%

Neuromodulation for the Treatment of Lower Urinary Tract Symptoms

Yamanishi

Kaga

Fuse

et al. 2015

LUTS

View full text Add to dashboard Cite

Neuromodulation therapy incorporates electrical stimulation to target specific nerves that control lower urinary tract symptoms (LUTS). The objectives of this article are to review the mechanism of action, the type of neuromodulation, and the efficacy of neuromodulation mainly according to the results of randomized controlled trials. Neuromodulation includes pelvic floor electrical stimulation (ES) using vaginal, anal and surface electrodes, interferential therapy (IF), magnetic stimulation (MS), percutaneous tibial nerve stimulation, and sacral nerve stimulation (SNS). The former four stimulations are used for external periodic (short-term) stimulation, and SNS are used for internal, chronic (long-term) stimulation. All of these therapies have been reported to be effective for overactive bladder or urgency urinary incontinence. Pelvic floor ES, IF, and MS have also been reported to be effective for stress urinary incontinence. The mechanism of neuromodulation for overactive bladder has been reported to be the reflex inhibition of detrusor contraction by the activation of afferent fibers by three actions, i.e., the activation of hypogastric nerve, the direct inhibition of the pelvic nerve within the sacral cord and the supraspinal inhibition of the detrusor reflex. The mechanism of neuromodulation for stress incontinence is contraction of the pelvic floor muscles through an effect on the muscle fibers as well as through the stimulation of pudendal nerves. Overall, cure and improvement rates of these therapies for urinary incontinence are 30-50, and 60-90% respectively. MS has been considered to be a technique for stimulating nervous system noninvasively. SNS is indicated for patients with refractory overactive bladder and urinary retention.

show abstract

Section: Introductionmentioning

confidence: 99%

Neuromodulation for the Treatment of Lower Urinary Tract Symptoms

Yamanishi

Kaga

Fuse

et al. 2015

LUTS

View full text Add to dashboard Cite

show abstract

“…Similar to the Mattiasson et al [20] study, Klutke et al [21] reported on significant improvement in patient quality of life and satisfaction in their 16-week, open-label trial of a population of 416 patients treated with tolterodine extended release plus behavioral intervention. In their study, all recruited patients reported dissatisfaction with prior antimuscarinic treatment alone (tolterodine or other antimuscarinic medication).…”

Section: Solifenacin and Tolterodine With Behavioral Treatmentmentioning

confidence: 79%

“…Mattiasson et al [20] reported the results of the SOLAR trial, a 643-patient, randomized, open-label trial of solifenacin with or without simplified bladder training. Bladder retraining was achieved via a single instruction sheet given to patients without any medical supervision or follow-up as to whether it had been implemented.…”

Section: Solifenacin and Tolterodine With Behavioral Treatmentmentioning

confidence: 99%

Clinical Differences Between Solifenacin and Tolterodine

Mongiu¹,

Lerner

2010

Curr Bladder Dysfunct Rep

View full text Add to dashboard Cite

Overactive bladder (OAB) is characterized by involuntary detrusor contractions that result in bothersome urinary symptoms. The estimated US prevalence of OAB is 16% among men and 16.9% among women, comprising some 37.4 million Americans. The mainstay of treatment is medication. Although all drugs have variable degrees of efficacy and tolerability, several have emerged that yield good clinical results with tolerable side effects. This review focuses on two frequently prescribed drugs, solifenacin and tolterodine, and compares their clinical efficacy. A PubMed review was conducted with "solifenacin" and "tolterodine" as search words. Articles that compared the two medications were reviewed for content and number of study participants. Those with the most relevant findings and the highest number of participants were included. Both solifenacin and tolterodine show clinical efficacy for the treatment of OAB. Solifenacin seems to have better results in some series, with similar side effects. Antimuscarinic therapy is effective as OAB treatment. Both solifenacin and tolterodine have good clinical efficacy. However, in headto-head trials, solifenacin seems to have somewhat better outcomes. Solifenacin, 5 mg, has less reported dry mouth than tolterodine, but at 10 mg, the incidence of dry mouth is similar.

show abstract

“…We identified a total of 12 studies (all prospective in nature) examining bladder training in combination with medications (Table ) . The bladder training regimens ranged from tailored or generic self‐administered behavioral therapy to pelvic floor physiotherapy sessions with a trained professional, while the medications used in each study were anticholinergics.…”

Section: Resultsmentioning

confidence: 99%

Combination therapy in overactive bladder‐untapped research opportunities: A systematic review of the literature

Kasman

Stave

Elliott

2019

Neurourology and Urodynamics

View full text Add to dashboard Cite

Aims Overactive bladder (OAB) affects over 17% of the population and significantly effect the health‐related quality of life. The treatments for OAB include first line (lifestyle modification, pelvic floor muscle training), second line (anticholinergic or beta‐3 agonist medications), and third line therapies (intradetrusor botulinum toxin injection, sacral neurostimulation [SNM], or percutaneous tibial nerve stimulation [PTNS]). For those with urinary incontinence secondary to OAB, complete continence is the goal of therapy, though cure rates are only 5% to 40%. The use of combination therapies can be employed in refractory OAB, however, the efficacy of pooled modalities is relatively unknown. Our objective was to determine the volume of data supporting combination therapy in treating OAB. Methods We systematically reviewed PubMed, EMBASE, the Cochrane Library, and Google Scholar for articles published before October 2018. Each was independently reviewed by two reviewers and examined in detail if they met inclusion criteria. Results A total of 32 studies met inclusion criteria and were reviewed. Most large prospective studies evaluated combinations of medications with behavioral therapy or medications together. Combination therapy studies of third‐line treatments were rare and centered on medication with PTNS. No studies examined intradetrusor botulinum toxin injections in combination with another therapy and only one retrospective study briefly examined SNM therapy in combination with medication. Conclusion Combination therapy, with certain first, second, and third‐line OAB therapies, appears to be efficacious. There is a further need for carefully designed combination therapy studies, particularly those including third line modalities.

show abstract

Efficacy of simplified bladder training in patients with overactive bladder receiving a solifenacin flexible‐dose regimen: results from a randomized study

Cited by 29 publications

References 19 publications

Neuromodulation for the Treatment of Lower Urinary Tract Symptoms

Neuromodulation for the Treatment of Lower Urinary Tract Symptoms

Clinical Differences Between Solifenacin and Tolterodine

Combination therapy in overactive bladder‐untapped research opportunities: A systematic review of the literature

Contact Info

Product

Resources

About